Last quarter (Q4 2022), Circassia Pharmaceuticals's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Circassia Pharmaceuticals's net income was £―. See Circassia Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	£ 36.80M	£ 31.30M	£ 27.90M	£ 23.90M	£ 34.60M
Cost of Revenue	-	£ 10.30M	£ 9.10M	£ 8.90M	£ 7.60M	£ 9.10M
Gross Profit	-	£ 26.50M	£ 22.20M	£ 19.00M	£ 16.30M	£ 25.50M
Operating Expense	-	£ 21.90M	£ 20.40M	£ 23.30M	£ 33.60M	£ 89.30M
Operating Income	-	£ 4.60M	£ 1.80M	£ -4.30M	£ -17.30M	£ -63.80M
Net Non Operating Interest Income Expense	-	£ 600.00K	-	£ 300.00K	£ -200.00K	£ -100.00K
Other Income Expense	-	£ -200.00K	£ -8.20M	-	-	-
Pretax Income	-	£ 4.10M	£ 10.50M	£ -2.10M	£ -18.40M	£ -27.60M
Tax Provision	-	£ -5.40M	£ -3.60M	£ -4.40M	£ 8.40M	£ -10.80M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ 10.70M	£ 16.10M	£ 3.60M	£ -33.50M	£ -48.30M
Basic EPS	-	£ 0.03	£ 0.07	£ 0.01	£ -0.09	£ -0.13
Diluted EPS	-	£ 0.02	£ 0.07	£ 0.01	£ -0.09	£ -0.13
Basic Average Shares	-	£ 420.21M	£ 419.20M	£ 412.60M	£ 381.86M	£ 373.70M
Diluted Average Shares	-	£ 449.28M	£ 443.00M	£ 435.83M	£ 381.86M	£ 373.70M
Dividend Per Share	-	£ 0.01	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	£ -0.11
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	£ 32.20M	£ 29.50M	£ -32.20M	£ 41.20M	£ 98.40M
Net Income From Continuing And Discontinued Operation	-	£ 10.70M	£ 16.10M	£ 3.60M	£ -33.50M	£ -48.30M
Normalized Income	-	£ -1.30M	£ 6.90M	£ -7.20M	£ -26.80M	£ -16.80M
Interest Expense	-	-	-	-	£ 100.00K	£ 100.00K
EBIT	-	£ 4.30M	£ 10.80M	£ -2.00M	£ -18.30M	£ -27.50M
EBITDA	-	£ 8.70M	£ 15.40M	£ -2.00M	£ -9.30M	£ -12.30M

Currency in GBP

Circassia Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing